EHA 2024 | The impact of the approval of pirtobrutinib on the treatment landscape for patients with CLL
Ryan Jacobs
• 16 Jun 2024
Ryan Jacobs, MD, Atrium Health Levine Cancer Institute, Charlotte, NC, discusses the impact of the recent approval of pirtobrutinib, a third-generation BTK inhibitor (BTKi), as a third-line treatment for chronic lymphocytic leukemia (CLL). Dr Jacobs highlights that this was a setting in which patients lacked safe and effective treatment options. Pirtobrutinib is well-tolerated and effective compared to other agents tested in this space, such as duvelisib, a PI3 kinase inhibitor. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
